GSK to acquire cancer drugmaker Nuvalent for $10.6B
What's the deal? British pharma giant GSK has agreed to buy US cancer treatment firm Nuvalent for $10.6 billion. The all-cash deal, announced on 9 June 2026, will give GSK access to Nuvalent's pipeline of next-generation lung cancer therapies — most notably treatments targeting ROS1 and ALK gene mutations in non-small cell lung cancer. GSK will pay $124 per share via a tender offer, a 40% premium to Nuvalent's last closing price.
Nuvalent, based in Cambridge, Massachusetts, has no approved products on the market yet. Its lead candidates, zidesamtinib and neladalkib, are in late-stage clinical trials and under FDA review, making this a bet on future revenue.
Why now? GSK has been under pressure to bolster its oncology portfolio as several of its older drugs approach patent expiry. The company has flagged cancer treatment as a priority growth area, and Nuvalent's pipeline fits squarely into that strategy.
Competition for promising oncology assets has intensified across the pharma industry, with rivals like AstraZenecaDealroom has a profile for this one. Try Dealroom → and PfizerDealroom has a profile for this one. Try Dealroom → also spending billions on cancer-focused acquisitions.
What could go wrong? Nuvalent's drugs haven't yet received regulatory approval. Late-stage trials can still fail, and even successful candidates face a long road through review before generating revenue. Paying $10.6 billion for a pre-revenue company carries significant risk if clinical results disappoint. Integration is another question — retaining key scientific talent will be critical to keeping Nuvalent's programmes on track.
The signal: This deal reflects a broader wave of big pharma buying its way into the next generation of cancer treatments. As blockbuster drugs lose patent protection, companies are racing to replenish their pipelines through acquisition. It also underscores the premium that precision oncology commands, with drugs targeting specific genetic mutations representing the frontier of cancer care.
Read more: GSK · Financial Times · CNBC · The Guardian
